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The covalent modification of intracellular proteins by O-linked
-N-acetylglucosamine (O-GlcNAc) is emerging as a crucial regula-
tory posttranslational modification akin to phosphorylation. Nu-
merous studies point to the significance of O-GlcNAc in cellular
processes such as nutrient sensing, protein degradation, and gene
expression. Despite its importance, the breadth and functional
roles of O-GlcNAc are only beginning to be elucidated. Advances in
our understanding will require the development of new strategies
for the detection and study of O-GlcNAc-modified proteins in vivo.
Herein we report the direct, high-throughput analysis of O-GlcNAc-
glycosylated proteins from the mammalian brain. The proteins
were identified by using a chemoenzymatic approach that exploits
an engineered galactosyltransferase enzyme to selectively label
O-GlcNAc proteins with a ketone-biotin tag. The tag permits
enrichment of low-abundance O-GlcNAc species from complex
mixtures and localization of the modification to short amino acid
sequences. Using this approach, we discovered 25 O-GlcNAc-
glycosylated proteins from the brain, including regulatory proteins
associated with gene expression, neuronal signaling, and synaptic
plasticity. The functional diversity represented by this set of
proteins suggests an expanded role for O-GlcNAc in regulating
neuronal function. Moreover, the chemoenzymatic strategy de-
scribed here should prove valuable for identifying O-GlcNAc-
modified proteins in various tissues and facilitate studies of the
physiological significance of O-GlcNAc across the proteome.
Protein posttranslational modifications (PTMs) represent animportant mechanism for the regulation of cellular physiology
and function. The covalent addition of phosphate, acetate, carbo-
hydrate, and other chemical groups extends the capabilities of
proteins and provides a selective and temporal means of controlling
protein function (1, 2). Despite the importance of PTMs, their
extent and significance are only beginning to be understood. Our
laboratory has been investigating O-linked -N-acetylglucosamine
(O-GlcNAc) glycosylation, the covalent attachment of -N-
acetylglucosamine to serine or threonine residues of proteins (3, 4).
Unlike most carbohydrate modifications, O-GlcNAc is dynamic and
intracellular and, as such, shares common features with protein
phosphorylation (3). Nearly 80 proteins bearing the O-GlcNAc
group have been identified to date, including transcription factors,
cytoskeletal proteins, protein kinases, and nuclear pore proteins
(4). Recent studies have elucidated diverse roles for the O-GlcNAc
modification, ranging from nutrient sensing to the regulation of
proteasomal degradation and gene silencing (3, 5). Moreover,
perturbations in O-GlcNAc levels have been associated with disease
states such as cancer, Alzheimer’s, and diabetes (3, 4).
Several lines of evidence suggest an important role for O-
GlcNAc in the brain. First, activation of protein kinase A or C
pathways leads to reduced levels of O-GlcNAc in certain protein
fractions from cerebellar neurons (6), suggesting an intriguing,
dynamic interplay between the two modifications. Second, O-
GlcNAc transferase (OGT), the enzyme that catalyzes the
modification, is most abundant in the brain and pancreas (7).
Interestingly, the activity of OGT appears to be modulated by
complex mechanisms, including differential splicing, interaction
with regulatory partners, and regulation via PTMs (7). Finally,
a critical role for O-GlcNAc in the brain is suggested by its
presence on proteins important for neuronal function and
pathogenesis such as cAMP-responsive element binding protein
(CREB) (8) and -amyloid precursor protein (APP) (4).
Despite strong evidence of its significance, the O-GlcNAc mod-
ification has been definitively linked to only a handful of proteins
from the brain (9). Efforts to identify proteins have been challenged
by the difficulty of detecting the modification in vivo. Like many
PTMs, O-GlcNAc is often dynamic, substoichiometric, and preva-
lent on low-abundance regulatory proteins. The sugar is both
enzymatically and chemically labile, being subject to reversal by
cellular glycosidases and facile fragmentation during MS analysis.
As with many protein kinases, the lack of a well defined consensus
sequence for OGT has precluded the determination of in vivo
modification sites based on primary sequence alone.
Several powerful methods have been reported for the identifi-
cation of O-GlcNAc-modified proteins. Proteins have been tritium-
labeled (10), enriched with lectins or antibodies (11, 12), or
chemically tagged by metabolic labeling or BEMAD (-elimination
followed by Michael addition with DTT) (12, 13). However, none
of the existing methods is ideally suited to the direct, high-
throughput identification of O-GlcNAc proteins from tissues or cell
lysates. For instance, the tritium methodology is labor intensive and
lacks sensitivity, necessitating purification of relatively large
amounts of protein. Enrichment of O-GlcNAc proteins using
antibody or lectin chromatography has not afforded direct obser-
vation of O-GlcNAc-glycosylated peptides and thus cannot rule out
false-positives (12). While metabolic labeling has been demon-
strated to identify the known, highly glycosylated protein p62 (13),
it has not been applied to map glycosylation sites. Moreover,
cellular uptake requirements may limit its broad application to
tissues. Although the BEMAD approach can be used to map sites
on purified proteins and protein complexes, it is an inherently
destructive technique that requires extensive controls to establish
whether a peptide contains a phosphate, O-GlcNAc, or complex
O-linked carbohydrate group (12).
A robust strategy for exploring the O-GlcNAc proteome would
permit investigations into the breadth of the modification and its
potential functions across various tissues and species. Direct detec-
tion of the O-GlcNAc moiety would enable conclusive identifica-
tion of the glycoproteins and localize the modification to specific
functional domains, a prerequisite for understanding the physio-
logical role of the modification. Moreover, such an approach might
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also allow for quantitative comparisons of glycosylation levels in
cellular or disease states.
We recently reported a chemoenzymatic strategy for the rapid
and sensitive detection of purified O-GlcNAc proteins (14). Here,
we describe extension of the approach to the direct, high-
throughput identification of O-GlcNAc proteins from the mamma-
lian brain. Using this strategy, 25 O-GlcNAc-modified proteins have
been identified, including regulatory proteins associated with gene
expression, neuronal signaling, and synaptic plasticity. The diversity
represented by this set of proteins provides insight into the role of
O-GlcNAc in neuronal function.
Materials and Methods
Chemoenzymatic Labeling, Biotinylation, and Avidin Enrichment of
-Crystallin. The A chain of bovine lens -crystallin (8.7 g,
Sigma-Aldrich) was incubated with the unnatural UDP substrate
(14) (750 M), and Y289L GalT (15) in 20 mM Hepes (pH 7.9)
containing 5 mM MnCl2 and 100 mM NaCl for 12 h at 4°C. The
reactions were then diluted 2-fold with saturated urea, 2.7 M
NaOAc (pH 3.9) (50 mM final concentration, pH 4.8), and N-
(aminoxyacetyl)-N-(D-biotinoyl) hydrazine (5 mM final concen-
tration, Dojindo, Gaithersburg, MD), and incubated with gentle
shaking for 20–24 h at 23°C. The tagged A-crystallin was excised
from a Coomassie-stained gel and digested with trypsin (Promega)
essentially as described by Shevchenko et al. (16). Avidin affinity
chromatography and liquid chromatography (LC)–tandem MS
(MSMS) analysis were performed as described below.
Preparation of Rat Forebrain Extracts. The forebrains of Sprague–
Dawley rats (Charles River Laboratories) were dissected on ice,
lysed into 10 vol of homogenization buffer, and fractionated into
nuclear and S100 cytoplasmic components as described by Dignam
et al. (17), except that protease inhibitors, phosphatase inhibitors,
and a hexosaminidase inhibitor (50 mM GlcNAc) (18) were added
to the buffers. Before labeling, the extracts were dialyzed into 20
mM Hepes (pH 7.3), 0.1 M KCl, 0.2 mM EDTA, 0.2% Triton
X-100, and 10% glycerol.
Chemoenzymatic Labeling of Cellular Extracts. Extract (1–10 mg; 1–3
mgml) was incubated with 5 mM MnCl2, 1.25 mM ADP, 0.5 mM
unnatural UDP substrate, and Y289L GalT (25 ngl) for 12–14 h
at 4°C. After enzymatic labeling, extracts were dialyzed into dena-
turing buffer (5 M urea50 mM NH4HCO3100 mM NaCl, pH 7.8;
3  2 h). The pH was adjusted with 2.7 M NaOAc (pH 3.9) (final
concentration 50 mM, pH 4.8). Aminoxy biotin (2.75 mM) was
added, and the reactions were incubated as described for A-
crystallin. Extracts were diluted with 3 M NH4HCO3 (pH 9.6) (50
mM final concentration, pH 8) and dialyzed (1 2 h, 1 10 h) into
6 M urea, 50 mM NH4HCO3 (pH 7.8), and 100 mM NaCl, followed
by either denaturing buffer (4 M urea50 mM NH4HCO310 mM
NaCl, pH 7.8) or nondenaturing buffer (50 mM NH4HCO310 mM
NaCl, pH 7.8).
Proteolytic Digestion and Cation ExchangeAvidin Affinity Chroma-
tography. Nondenatured extracts from the previous step were
concentrated and denaturedreduced as described in the isotope-
coded affinity tag protocol from Applied Biosystems. Proteins were
then alkylated with 15 mM iodoacetamide for 45 min in the dark,
diluted to 0.04% SDS with 50 mM NH4HCO3 (pH 7.8), and
digested with trypsin or GluC (20–30 ngl) for 12–14 h at 37°C.
Urea-denatured extracts were diluted with 50 mM NH4HCO3 (pH
7.8) after the reduction (10 min) and alkylation steps, and subjected
to protease digestion as described above.
Proteolytic digests conducted in the presence of urea were
desalted with peptide macrotrap cartridges (Michrom Biore-
sources, Auburn, CA). Digests conducted without urea were acid-
ified with 1% aqueous trifluoroacetic acid and diluted into cation
exchange load buffer (Applied Biosystems). Cation exchange chro-
matography was performed on 1–3 mg of lysate as described by the
manufacturer, except that peptides were eluted with a step gradient
of 40, 100, 200, and 350 mM KCl in 5 mM KH2PO4 containing 25%
CH3CN. Fractionated peptides were enriched by avidin chroma-
tography (Applied Biosystems) as described by the manufacturer
except that the washes were tripled in volume.
-EliminationMichael Addition of Avidin-Purified Peptides. After
avidin chromatography, a portion of the S100 lysate fraction (40
mM KCl elution) was subjected to -eliminationMichael addition
(12) by using 25 mM butanethiol, and reactions were stopped with
AcOH.
LC-MS Analysis of Avidin-Enriched Biotinylated Peptides. Automated
nanoscale RP-HPLCelectrospray ionization (ESI)MS was per-
formed with an HPLC pump, autosampler (Agilent Technologies,
Palo Alto, CA), and linear ion trap mass spectrometer (Thermo
Electron, San Jose, CA) with a variation of the ‘‘vented column’’
approach described by Licklider et al. (19). For data-dependent
experiments, the mass spectrometer was programmed to record a
full-scan ESI mass spectrum (mz 500–2,000) followed by five
data-dependent MSMS scans (relative collision energy  35%;
3.5-Da isolation window). Precursor ion masses for candidate
glycosylated peptides were identified by a computer algorithm
(Charge Loss Scanner; developed in-house with VISUAL BASIC 6.0)
that inspected product ion spectra for peaks corresponding to losses
of the ketone-biotin and ketone-biotin-GlcNAc moieties. Up to
eight candidate peptides at a time were analyzed in subsequent
targeted MS4 experiments to derive sequence information. See Fig.
4, which is published as supporting information on the PNAS web
site, for additional information on LC-MS and database querying.
Results
Approach Toward the Direct, High-Throughput Identification of O-
GlcNAc-Modified Proteins. Previously, we reported a chemoenzy-
matic strategy for the detection of purified O-GlcNAc-glycosylated
proteins (14). Our approach took advantage of an engineered
-1,4-galactosyltransferase (GalT) enzyme to transfer a ketone-
containing galactose analogue selectively to the C-4 hydroxyl of
GlcNAc. Once transferred, the ketone functionality was reacted
with an aminooxy biotin nucleophile, permitting the rapid, chemi-
luminescence detection of the O-GlcNAc-modified proteins. We
reasoned that this biotin tagging approach could be extended to
enrich O-GlcNAc-glycosylated species from complex mixtures (Fig.
1). Previous studies have demonstrated the importance of enrich-
ment strategies for the detection of PTMs (20). In our case, proteins
from cellular lysates would be selectively labeled with the ketone-
biotin handle and proteolytically digested, and the glycopeptides
would be captured by using avidin affinity chromatography. Mass
spectrometric analysis of the enriched glycopeptides would afford
the proteomewide identification of novel glycosylated proteins.
Importantly, the approach would also permit the direct detection of
modified peptides, enabling simultaneous mapping of O-GlcNAc to
specific functional domains within a protein.
Application of the Strategy to the A Chain of Bovine -Crystallin. We
first demonstrated that O-GlcNAc-modified peptides could be
selectively enriched by using peptide mixtures from A-crystallin.
A-Crystallin contains one major site of glycosylation with an
estimated stoichiometry of 10% (21). As such, it has proven to be
a challenging target for MS analysis, requiring sophisticated quad-
rupole time-of-flight instrumentation (21) or in-line lectin affinity
chromatography (22).A-Crystallin was enzymatically labeled with
the ketone functionality and chemically reacted with an aminooxy
biotin derivative. After tryptic digestion and avidin chromatogra-
phy, enrichment of the expected glycosylated species was observed
(Fig. 2). LC-MS analysis indicated a peak corresponding to the mass
of the O-GlcNAc-modified peptide 158AIPVSREEKPSSAPSS173
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labeled with the ketone-biotin tag (mz 787.86). Notably, the
ketone-biotin moiety produced a unique fragmentation pattern
upon collision-induced dissociation (CID), which provided unam-
biguous indication of an O-GlcNAc containing peptide. Specifi-
cally, predominant loss of the ketone-biotin moiety (515.3 Da) was
readily observed upon CID, followed by subsequent loss of the
GlcNAc group (203.1 Da) during MS3 experiments. MS3 analysis
localized the GlcNAc moiety on the peptide to the known glyco-
sylation site, Ser-162 (21), and higher-order MS analysis afforded
sequence confirmation of the peptide (Fig. 5 which is published as
supporting information on the PNAS web site).
Exploration of the O-GlcNAc Proteome of the Brain. Having demon-
strated the tagging and capture of an O-GlcNAc-glycosylated
peptide from A-crystallin, we applied the approach to the O-
GlcNAc proteome of the mammalian brain. Rat brain lysates were
separated into nuclear and S100 cytoplasmic fractions, labeled with
the tag, and digested with trypsin. We also subjected a portion of
the samples to proteolytic digestion with GluC to broaden the scope
of analysis and generate confirmatory peptide sequences. Because
of the overall complexity of the sample, the digested peptides were
fractionated via strong cation exchange chromatography before
avidin affinity chromatography.
Nearly 100 peptides containing the characteristic signature loss of
the ketone-biotin tag were observed by LC-MSMS. Fig. 3a shows
an averaged electrospray ionization mass spectrum of ions eluting
from the LC column with retention time of 17.0–18.1 min. Peaks
corresponding to peptides with the diagnostic signature were sub-
sequently selected for targeted MS4 analysis. Notably, the vast
majority of peaks in this region contained the GlcNAc-ketone-
biotin moiety, demonstrating significant enrichment of modified
peptides. The MSMS spectrum of a representative peptide (mz
789.2) (Fig. 3b), illustrates the characteristic loss of a ketone-biotin
moiety (mz  925.5) and GlcNAc-ketone-biotin moiety (mz
823.9). Higher-order MS analysis generated a definitive series of b
and y ions (Fig. 3c), and database searching identified the peptide
as belonging to the protein synaptopodin. Notably, alternative MS
instrumentation and techniques such as a quadrupole time-of-flight
mass spectrometer (21) can be used to obtain sequencing informa-
tion of species exhibiting the characteristic loss signature.
Using this approach, we successfully sequenced 34 unique pep-
tides corresponding to 25 proteins from rat brain (Table 1).
Importantly, two of the proteins, microtubule-associated protein
(MAP) 2B and host cell factor (HCF) have been reported to be
O-GlcNAc-glycosylated (23, 24), providing strong validation of our
methodology. In addition, our results extend earlier reports by
establishing distinct amino acid stretches within each protein that
bear the modification. Two sites of glycosylation were identified in
the N-terminal region of MAP2B. In accordance with a demon-
strated interaction between the N-terminal region of HCF and both
a GlcNAc-specific antibody and lectin (24), we observed four
distinct sites within three peptides in the N-terminal region of HCF.
Fig. 1. Chemoenzymatic strategy for identifying O-GlcNAc-glycosylated proteins from cellular lysates.
Fig. 2. Application of the strategy toward A-crystallin. (a) MS analysis
revealed the tagged O-GlcNAc peptide 158AIPVSREEKPSSAPSS173 (mz 787.86).
The tag provided a diagnostic signature by MSMS. The MSMS spectrum of
the triply charged precursor ion revealed the signature loss of the ketone-
biotin moiety to yield the doubly charged GlcNAc-modified peptide (mz
922.85) as the predominant species. MS3 analysis revealed the loss of the
GlcNAc moiety to yield the unmodified peptide (mz 821.64) and several y and
b fragment ions containing the GlcNAc moiety that were used to establish the
glycosylation site as Ser-162. Glycosylated y and b ions are indicated with the
subscript G. MS4 analysis generated additional y and b ions as well as several
internal fragment ions that were used to sequence the peptide. Note that the
loss of the ketone-biotin moiety is associated with a loss of charge; therefore
the major mz value of the fragment ion in the MS2 spectrum is greater than
that of the precursor ion observed by MS. (b) Summary of the y and b fragment
ions.
13134  www.pnas.orgcgidoi10.1073pnas.0403471101 Khidekel et al.
We also identified O-GlcNAc on erythrocyte protein band 4.1-like
3 within a region that shares significant sequence identity to a
reported glycopeptide from human erythrocyte membrane protein
band 4.1 (25).
In addition to known proteins, our approach enabled the iden-
tification of 23 additional O-GlcNAc-glycosylated proteins from the
mammalian brain (Table 1). The proteins fall into a broad range of
functional classes (26), including those involved in neuronal signal-
ing, transcriptional regulation, and synaptic plasticity (Fig. 6, which
is published as supporting information on the PNAS web site).
Consistent with studies demonstrating the presence of O-GlcNAc
on transcription factors and RNA polymerase II, we identified a
large number of proteins involved in transcription. In addition to
low-abundance transcription factors, we found O-GlcNAc on tran-
scriptional coactivators, corepressors, and chromatin remodeling
enzymes, which suggests expanded roles for O-GlcNAc in tran-
scriptional control.
Notably, our methodology also afforded the simultaneous de-
tection of multiple PTMs. For instance, we observed an O-GlcNAc-
modified peptide with a characteristic loss of 98 Da upon collision-
induced dissociation, consistent with phosphorylation within the
same peptide (Fig. 7, which is published as supporting information
on the PNAS web site). Moreover, two O-GlcNAc modifications
were identified within the same peptide of HCF.
Merging the Technology with -Elimination Strategies to Map Gly-
cosylation Sites. The mapping of specific O-GlcNAc glycosylation
sites is inherently difficult due to the lability of the glycosidic linkage
upon collision-induced dissociation and the preference of OGT for
sequences rich in serine, threonine, and proline residues. Although
we successfully narrowed the sites of O-GlcNAc glycosylation to
short amino acid sequences, the features noted above limited our
ability to perform site identification on all but a few sequences. To
address this issue, we combined precedented -elimination strate-
gies with our methodology to localize specific modification sites.
Previous studies have shown that glycosylated and phosphorylated
serinethreonine residues as well as carboxyamido-modified cys-
teine residues undergo -elimination to form dehydroalanine-
methyldehydroalanine under strong alkaline conditions (12, 27).
Subsequent Michael addition of a thiol nucleophile generates a
stable sulfide adduct. We first labeled S100 cytoplasmic lysates with
our ketone-biotin tag and enriched the O-GlcNAc glycopeptides by
using avidin chromatography as described. One of the enriched
fractions was then selected for -elimination, followed by butane-
thiol addition (Figs. 8 and 9, which are published as supporting
information on the PNAS web site). MSMS analysis of the
resultant peptides permitted localization of the glycosylation site on
HIV-1 Rev binding protein from seven possible residues within the
peptide 360APVGSVVSVPSHSSASSDK378 to Ser-372 or Ser-373.
Notably, MSMS analysis before -elimination conclusively dem-
onstrated that the original peptide was O-GlcNAc-glycosylated,
rather than phosphorylated or modified with a complex carbohy-
drate. With further refinement of the -elimination methodology
toward complex mixtures, we anticipate that the combined ketone-
labeling and -elimination approaches will be a powerful tool for
identifying specific O-GlcNAc modification sites.
Discussion
Herein we report a direct, high-throughput analysis of O-GlcNAc
glycosylated proteins from the mammalian brain. The proteins were
identified by using a chemoenzymatic approach that exploits an
engineered galactosyltransferase enzyme to selectively label Glc-
NAc proteins with a ketone-biotin tag. The tag provides both a
straightforward means to enrich low-abundance O-GlcNAc pep-
tides from complex mixtures and a unique signature upon MSMS
for unambiguous identification of the O-GlcNAc-glycosylated spe-
cies. In contrast to reported antibody, lectin, and metabolic labeling
methods (11–13), the strategy provides direct evidence of O-
GlcNAc glycosylation and permits mapping of modification sites to
short amino acid sequences. The ability to localize O-GlcNAc is
essential for surveying its distribution across the proteome and
understanding its functional significance on a given protein or
family of proteins.
An exciting feature of the approach is its potential to explore the
interplay among PTMs (2, 28). In this study, we identified two
peptides that contained more than one PTM. For instance, the
N-terminal domain of HCF showed two O-GlcNAc moieties within
the same peptide, and a second peptide exhibited evidence of both
phosphorylation and glycosylation. Notably, all O-GlcNAc proteins
known to date are phosphoproteins, and increasing evidence sug-
gests that glycosylation functionally antagonizes phosphorylation in
many cases (3, 8). The approach reported herein involves a non-
destructive technique that does not require the removal of other
PTMs to study O-GlcNAc. As such, the strategy should permit a
direct examination of whether specific glycosylation and phosphor-
ylation events are mutually exclusive in vivo, as suggested for the
C-terminal domain of RNA polymerase II (29), or whether the two
modifications coexist, as recently reported for the transcription
factor signal transducer and activator of transcription 5 (Stat5) (30).
Thus, the strategy is complementary to top-down MS approaches
that can be used to simultaneously interrogate multiple PTMs from
intact proteins (31).
The chemoenzymatic approach can also be combined with
existing -elimination strategies, providing a powerful tool to
identify precise sites of glycosylation. Notably, emerging MS tech-
niques such as electron transfer dissociation, which has been
successfully used to map phosphorylation sites, could also be
Fig. 3. Analysis of tagged O-GlcNAc peptides from brain lysates. (a) Summed
mz spectrum of ions eluting from the LC column with retention time 17.0–
18.1 min. Peaks indicated by * represent peptides that yielded the diagnostic
ketone-biotin and GlcNAc-ketone-biotin loss signature upon MSMS. (b)
MSMS spectrum of a representative peak (mz  789.23), showing loss of a
ketone-biotin moiety (mz  925.50) and GlcNAc-ketone-biotin moiety (mz
823.92). Fragmentation during MS4 analysis yielded numerous b and y ions,
which permitted sequencing of the peptide. (c) Prominent fragment ions used
to identify the peptide as 203VSGHAAVTTPTKVYSE218 from synaptopodin.
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combined with our methodology to directly identify glycosylation
sites and abrogate the need for -elimination (32).
In this work, we demonstrated the power of our approach by
identifying 25 O-GlcNAc-glycosylated proteins from the mamma-
lian brain. Over the last 20 years, the O-GlcNAc modification has
been established on80 proteins (4). Thus, our findings represent
a significant expansion in the number of known O-GlcNAc pro-
teins, and they provide insights into the breadth of the modification
and its potential functions in the brain.
Consistent with previous studies demonstrating an important
role for O-GlcNAc in transcriptional regulation, we identified two
unique transcription factors, sry-related high mobility group box 2
(Sox2) and activating transcription factor 2 (ATF-2). Sox2 is a
member of the high mobility group box superfamily of minor
groove DNA-binding proteins (33), proteins believed to govern cell
fate decisions during diverse developmental processes. Although
primarily known for its role in embryogenesis, Sox2 has also been
detected in the adult central nervous system (34). ATF-2 is a
Table 1. O-GlcNAc glycosylated proteins from the mammalian brain
Protein NCBI entry Function Peptide sequence Residues
Transcriptional regulation
Sox2 (sry-related high mobility group
box 2)
31543759* Transcription factor SEASSSPPVVTSSSHSR 248–264
ATF-2 13591926 Transcription factor, histone
acetyltransferase
AALTQQHPPVTDGDTVK 262–278
HCF 34881756 Transcriptional regulator, chromatin
associated factor
TAAAQVGTSVSSAANTSTRPIITVHK† 620–645
HCF 34881756 Transcriptional regulator, chromatin
associated factor
VMSVVQTK
SPITIITTK
691–698
802–810
SRC-1 (steroid receptor coactivator 1) 34863079 Transcriptional coactivator for nuclear
receptors
INPSVNPGISPAHGVTR 188–204
CCR4-NOT4 34855140 Global transcriptional regulator,
mRNA metabolism
SNPVIPISSSNHSAR 329–343
CCR4-NOT subunit 2 34864872 Global transcriptional regulator,
mRNA metabolism
SLSQGTQLPSHVTPTTGVPTMSLHTPPSPSR 79–109
TLE-4 (transducin-like enhancer
protein 4)
9507191 Transcriptional corepressor TDAPTPGSNSTPGLRPVPGKPPGVDPLASSLR 298–329
RNA-binding motif protein 14 16307494* Transcriptional coregulator for steroid
receptors
AQPSVSLGAAYR 239–250
Nucleic acid-binding proteins
NFR-B (nuclear factor-related B) 34862978 DNA binding protein VPVTATQTK 896–904
Zinc finger RNA-binding protein 34854400 RNA binding protein AGYSQGATQYTQAQQAR 58–74
Intracellular transport
Hrb (HIV-1 Rev-binding protein) 34859394 RNA trafficking APVGSVVSVPSHSSASSDK‡ 360–378
GRASP55 (Golgi reassembly stacking
protein 2)
20301956 Membrane protein transport, Golgi
cisternae stacking
VPTTVEDR 423–430
Cellular organizationdynamics
Erythrocyte protein band 4.1-like 3 16758808 Cytoskeletal protein TITSETTSTTTTTHITK
TTSTTTTTHITKTVKGGISE
1026–1042
1031–1050
Erythrocyte protein band 4.1-like 1,
isoform L
11067407 Cytoskeletal protein DVLTSTYGATAETLSTSTTTHVTK 1460–1483
Erythrocyte protein band 4.1-like 1,
isoform L
11067407 Cytoskeletal protein TLSTSTTTHVTKTVKGGFSE 1472–1491
Spectrin beta chain (fodrin beta chain) 34879632 Axonalpre-synaptic cytoskeletal
protein
HDTSASTQSTPASSR 2354–2368
MAP1B 19856246 Axonogenesis TTTKTTRSPDTSAYCYE 2018–2034
MAP2B 111965 Dynamic assembly of microtubules at
dendrites
SSKDEEPQKDKADKVADVPVSE 366–387
MAP2B 111965 Dynamic assembly of microtubules at
dendrites
KADKVADVPVSE
TSSESPFPAKE
376–387
788–798
Cellular communicationsignal transduction
WNK-1 (lysine deficient protein kinase) 16758634 Signal transduction, ion homeostasis DGTEVHVTASSSGAGVVK
MGGSTPISAASATSLGHFTK
1584–1601
2043–2062
PDZ-GEF 34857578 Guanine nucleotide exchange factor
for RAP12
ISSRSSIVSNSSFDSVPVSLHDE 1211–1233
PDZ-GEF 34857578 Guanine nucleotide exchange factor
for RAP12
SSFDSVPVSLHDER
SVPVSLHDE
1221–1234
1225–1233
Synaptopodin 11067429 Dendritic spine formation VSGHAAVTTPTKVYSE 203–218
Bassoon 9506427 Synaptic vesicle cycling VTQHFAK§ 1338–1444
Uncharacterized proteins
Hypothetical protein FLJ31657 34855501 Unknown IGGDLTAAVTK 196–206
1300019H17RIKEN protein 34880180 Unknown EAALPSTK 286–293
KIAA1007 protein 34851212 Unknown TVTVTKPTGVSFK 1051–1063
DACA-1 homolog 34861007 Unknown IGDVTTSAVK 271–280
*Mouse proteins identified in the National Center for Biotechnology Information (NCBI) database. Corresponding rat orthologs were identified in the Celera
database.
†We identified two distinct sites of O-GlcNAc glycosylation on this peptide.
‡The site of modification was localized to Ser-372 or Ser-373 by using a combination of chemoenzymatic tagging and -elimination.
§Confirmed by peptide synthesis and MS sequencing analysis (see Fig. 10, which is published as supporting information on the PNAS web site).
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transcription factor that is enriched in the brain (35), and possesses
an intrinsic histone acetyltransferase (HAT) activity required for
activating transcription (36). As O-GlcNAc has been implicated in
nutrient sensing and the development of insulin-resistant diabetes
(3, 4), it is interesting that ATF-2 appears to play multiple roles in
glucose homeostasis. For instance, ATF-2 has been shown to
up-regulate transcription from the insulin promoter in human
pancreatic  cells in a Ca2calmodulin-dependent protein kinase
IV-dependent manner (37). Moreover, recent studies indicate that
ATF-2 activates the gluconeogenic gene phosphoenolpyruvate
carboxykinase in HepG2 hepatic cells upon retinoic acid induction
(38). Notably, the region of glycosylation lies in a proline-rich
stretch near a motif essential for the HAT activity of ATF-2.
Phosphorylation in the N-terminal transactivation domain of
ATF-2 (Thr-69 and Thr-71) up-regulates its HAT activity (36). It
will be important to examine in this instance whether glycosylation
and phosphorylation act in opposition.
Although transcription factors and RNA polymerase II have
been shown to be glycosylated, other important elements of the
transcriptional machinery have not been well documented. In this
study, we demonstrated O-GlcNAc on unique transcriptional pro-
teins, including coactivators and corepressors. This finding suggests
broader roles for O-GlcNAc in regulating transcription than pre-
viously recognized. For instance, we found the modification on two
proteins (including a ubiquitin ligase) in the carbon catabolite
repression 4-negative on TATA-less (CCR4-NOT), a large protein
complex involved in mRNA metabolism and the global control of
gene expression (39). In addition, O-GlcNAc was identified on
steroid receptor coactivator-1 (SRC-1), a protein involved in chro-
matin remodeling that functions as a transcriptional coactivator for
estrogen, thyroid, and other nuclear receptors (40). Finally, O-
GlcNAc was found on HCF, a chromatin-associated factor that
interacts with both OGT and the Sin3A histone deacetylase com-
plex in vivo (24). Mammalian Sin3A interacts with OGT and
thereby synergistically represses transcription from both basal and
Sp-1-driven promoters (41). Here, we identified four distinct sites
of glycosylation within the N-terminal domain of HCF, a region
required for interaction with both OGT and Sin3A (24). It will be
interesting to examine the functional impact of HCF glycosylation
on its binding to Sin3A and OGT and on gene silencing.
Importantly, our results demonstrate that a number of proteins
involved in neuronal signaling and synaptic function are the targets
of O-GlcNAc glycosylation. For instance, we identified the modi-
fication of PDZ-GEF, a guanine nucleotide exchange factor that
activates the Ras-related GTPases Rap1 and Rap2 (42). PDZ-GEF
contains a PDZ domain, a protein-interacting module often in-
volved in the assembly of signal transduction complexes at the
synapse (43). Another O-GlcNAc protein is WNK-1 (With No
Lysine K), a serinethreonine protein kinase whose activation has
been linked to ion transport and hypertension (44). Moreover, we
identified two brain-enriched proteins important for synaptic func-
tion, synaptopodin and bassoon. The actin-associated protein syn-
aptopodin is essential for dendritic spine formation, with synap-
topodin-deficient mice exhibiting a lack of spine apparatuses and
impaired long-term potentiation and spatial learning (45). Bassoon,
a scaffolding protein of the cytomatrix assembled at the active zone,
plays a critical role in synaptic vesicle cycling (46). Taken together,
these findings reveal that O-GlcNAc glycosylation likely plays
critical roles in neuronal communication and synaptic function.
In summary, we demonstrate a chemoenzymatic strategy for the
high-throughput identification of O-GlcNAc-glycosylated proteins
from the mammalian brain. The approach permits the enrichment
and direct identification of O-GlcNAc-glycosylated peptides from
complex mixtures and can be combined with existing technologies
to map specific glycosylation sites. The generality of the method
should enable explorations of the O-GlcNAc proteome in any cell
type or tissue. Moreover, studies of the dynamic interplay among
PTMs and future extension of the methodology to quantitative
proteomics should be possible. Using the approach, we discovered
25 O-GlcNAc-glycosylated proteins from the brain, including reg-
ulatory proteins associated with gene expression, neuronal signal-
ing, and synaptic plasticity. The functional diversity represented by
this set of proteins suggests an expanded role for O-GlcNAc in
regulating neuronal function. We anticipate that further investiga-
tions of the proteins identified in this study, coupled with the
continued development of chemical tools, will provide insights into
the physiological importance of this posttranslational modification.
We thank Drs. Pradman Qasba and Boopathy Ramakrishnan for gen-
erously providing the mutant GalT enzyme, Hwan-Ching Tai and Scott
Brittain for helpful discussions, and Dr. Andrew Su for assistance with
Celera database searches. This research was supported by National
Institutes of Health Training Grant T32GM07616, a Parson’s Founda-
tion Fellowship (to N.K.), National Science Foundation CAREER
Award CHE-0239861, and an Alfred P. Sloan Fellowship.
1. Greengard, P. (2001) Science 294, 1024–1030.
2. Fischle, W., Wang, Y. & Allis, C. D. (2003) Nature 425, 475–479.
3. Slawson, C. & Hart, G. W. (2003) Curr. Opin. Struct. Biol. 13, 631–636.
4. Whelan, S. A. & Hart, G. W. (2003) Circ. Res. 93, 1047–1058.
5. Zhang, F., Su, K., Yang, X., Bowe, D. B., Paterson, A. J. & Kudlow, J. E. (2003) Cell 115,
715–725.
6. Griffith, L. S. & Schmitz, B. (1999) Eur. J. Biochem. 262, 824–831.
7. Iyer, S. P. N. & Hart, G. W. (2003) Biochemistry 42, 2493–2499.
8. Lamarre-Vincent, N. & Hsieh-Wilson, L. C. (2003) J. Am. Chem. Soc. 125, 6612–6613.
9. Cole, R. N. & Hart, G. W. (2001) J. Neurochem. 79, 1080–1089.
10. Roquemore, E. P., Chou, T. Y. & Hart, G. W. (1994) Methods Enzymol. 230, 443–460.
11. Cieniewski-Bernard, C., Bastide, B., Lefebvre, T., Lemoine, J., Mounier, Y. & Michalski,
J. C. (2004) Mol. Cell. Proteomics 3, 577–585.
12. Wells, L., Vosseller, K., Cole, R. N., Cronshaw, J. M., Matunis, M. J. & Hart, G. W. (2002)
Mol. Cell. Proteomics 1, 791–804.
13. Vocadlo, D. J., Hang, H. C., Kim, E. J., Hanover, J. A. & Bertozzi, C. R. (2003) Proc. Natl.
Acad. Sci. USA 100, 9116–9121.
14. Khidekel, N., Arndt, S., Lamarre-Vincent, N., Lippert, A., Poulin-Kerstien, K. G., Ra-
makrishnan, B., Qasba, P. K. & Hsieh-Wilson, L. C. (2003) J. Am. Chem. Soc. 125,
16162–16163.
15. Ramakrishnan, B. & Qasba, P. K. (2002) J. Biol. Chem. 277, 20833–20839.
16. Shevchenko, A., Wilm, M., Vorm, O. & Mann, M. (1996) Anal. Chem. 68, 850–858.
17. Dignam, J. D., Lebovitz, R. M. & Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475–1489.
18. Chou, T. Y., Hart, G. W. & Dang, C. V. (1995) J. Biol. Chem. 270, 18961–18965.
19. Licklider, L. J., Thoreen, C. C., Peng, J. & Gygi, S. P. (2002) Anal. Chem. 74, 3076–3083.
20. Kalume, D. E., Molina, H. & Pandey, A. (2003) Curr. Opin. Chem. Biol. 7, 64–69.
21. Chalkley, R. J. & Burlingame, A. L. (2001) J. Am. Soc. Mass Spectrom. 12, 1106–1113.
22. Haynes, P. A. & Aebersold, R. (2000) Anal. Chem. 72, 5402–5410.
23. Ding, M. & Vandre, D. D. (1996) J. Biol. Chem. 271, 12555–12561.
24. Wysocka, J., Myers, M. P., Laherty, C. D., Eisenman, R. N. & Herr, W. (2003) Genes Dev.
17, 896–911.
25. Inaba, M. & Maede, Y. (1989) J. Biol. Chem. 264, 18149–18155.
26. Schoof, H., Zaccaria, P., Gundlach, H., Lemcke, K., Rudd, S., Kolesov, G., Arnold, R.,
Mewes, H. W. & Mayer, K. F. (2002) Nucleic Acids Res. 30, 91–93.
27. Oda, Y., Nagasu, T. & Chait, B. T. (2001) Nat. Biotechnol. 19, 379–382.
28. Khidekel, N. & Hsieh-Wilson, L. C. (2004) Org. Biomol. Chem. 2, 1–7.
29. Kelly, W. G., Dahmus, M. E. & Hart, G. W. (1993) J. Biol. Chem. 268, 10416–10424.
30. Gewinner, C., Hart, G., Zachara, N., Cole, R., Beisenherz-Huss, C. & Groner, B. (2004)
J. Biol. Chem. 279, 3563–3572.
31. Kelleher, N. L. (2004) Anal. Chem. 76, 197A–203A.
32. Syka, J. E., Coon, J. J., Schroeder, M. J., Shabanowitz, J. & Hunt, D. F. (2004) Proc. Natl.
Acad. Sci. USA 101, 9528–9533.
33. Pevny, L. H. & Lovell-Badge, R. (1997) Curr. Opin. Genet. Dev. 7, 338–344.
34. Gure, A. O., Stockert, E., Scanlan, M. J., Keresztes, R. S., Jager, D., Altorki, N. K., Old, L. J.
& Chen, Y. T. (2000) Proc. Natl. Acad. Sci. USA 97, 4198–4203.
35. Herdegen, T. & Leah, J. D. (1998) Brain Res. Brain Res. Rev. 28, 370–490.
36. Kawasaki, H., Schiltz, L., Chiu, R., Itakura, K., Taira, K., Nakatani, Y. & Yokoyama, K. K.
(2000) Nature 405, 195–200.
37. Ban, N., Yamada, Y., Someya, Y., Ihara, Y., Adachi, T., Kubota, A., Watanabe, R., Kuroe,
A., Inada, A., Miyawaki, K., et al. (2000) Diabetes 49, 1142–1148.
38. Lee, M. Y., Jung, C. H., Lee, K., Choi, Y. H., Hong, S. & Cheong, J. (2002) Diabetes 51,
3400–3407.
39. Collart, M. A. (2003) Gene 313, 1–16.
40. Xu, J. & Li, Q. (2003) Mol. Endocrinol. 17, 1681–1692.
41. Yang, X., Zhang, F. & Kudlow, J. E. (2002) Cell 110, 69–80.
42. Rebhun, J. F., Castro, A. F. & Quilliam, L. A. (2000) J. Biol. Chem. 275, 34901–
34908.
43. Zhang, M. & Wang, W. (2003) Acc. Chem. Res. 36, 530–538.
44. Wilson, F. H., Disse-Nicodeme, S., Choate, K. A., Ishikawa, K., Nelson-Williams, C.,
Desitter, I., Gunel, M., Milford, D. V., Lipkin, G. W., Achard, J. M., et al. (2001) Science
293, 1107–1112.
45. Deller, T., Korte, M., Chabanis, S., Drakew, A., Schwegler, H., Stefani, G. G., Zuniga, A.,
Schwarz, K., Bonhoeffer, T., Zeller, R., et al. (2003) Proc. Natl. Acad. Sci. USA 100,
10494–10499.
46. Altrock, W. D., Tom Dieck, S., Sokolov, M., Meyer, A. C., Sigler, A., Brakebusch, C., Fassler,
R., Richter, K., Boeckers, T. M., Potschka, H., et al. (2003) Neuron 37, 787–800.
Khidekel et al. PNAS  September 7, 2004  vol. 101  no. 36  13137
CH
EM
IS
TR
Y
BI
O
CH
EM
IS
TR
Y
